血浆神经酰胺与心血管疾病风险：大规模脂质组学分析。

Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis.

机构信息

Saw Swee Hock School of Public Health, National University of Singapore (NUS), 12 Science Drive 2, #10-01, Singapore, 117549, Singapore.

NUS Graduate School for Integrative Sciences and Engineering, NUS, Singapore, 119077, Singapore.

出版信息

Metabolomics. 2020 Aug 20;16(9):89. doi: 10.1007/s11306-020-01709-8.

DOI:10.1007/s11306-020-01709-8

PMID:32816082

Abstract

INTRODUCTION

Sphingolipids are a diverse class of lipids with various roles in cell functions and subclasses such as ceramides have been associated with cardiovascular diseases (CVD) in previous studies.

OBJECTIVES

We aimed to measure molecularly-distinct sphingolipids via a large-scale lipidomic analysis and expand the literature to an Asian population.

METHODS

We performed a lipidomics evaluation of 79 molecularly distinct sphingolipids in the plasma of 2627 ethnically-Chinese Singaporeans.

RESULTS

During a mean follow-up of 12.9 years, we documented 152 cases of major CVD (non-fatal myocardial infarction, stroke and cardiovascular death). Total ceramide concentrations were not associated with CVD risk [hazard ratio (HR), 0.99; 95% CI 0.81-1.21], but higher circulating total monohexosylceramides (HR, 1.22; 95% CI 1.03, 1.45), total long-chain sphingolipids (C16-C18) (HR, 1.22; 95% CI 1.02, 1.45) and total 18:1 sphingolipids (HR, 1.21; 95% CI 1.01, 1.46) were associated with higher CVD risk after adjusting for conventional CVD risk factors.

CONCLUSIONS

Our results do not support the hypothesis that higher ceramide concentrations are linked to higher CVD risk, but suggest that other classes of sphingolipids may affect CVD risk.

摘要

简介

神经酰胺等鞘脂类是具有多种细胞功能的脂质，其亚类与心血管疾病（CVD）有关。

目的

我们旨在通过大规模脂质组学分析测量分子上不同的神经酰胺，并将文献扩展到亚洲人群。

方法

我们对 2627 名华裔新加坡人血浆中的 79 种分子上不同的神经酰胺进行了脂质组学评估。

结果

在平均 12.9 年的随访期间，我们记录了 152 例主要 CVD（非致命性心肌梗死、中风和心血管死亡）病例。总神经酰胺浓度与 CVD 风险无关[风险比（HR），0.99；95%置信区间（CI）0.81-1.21]，但循环总单己糖神经酰胺（HR，1.22；95% CI 1.03,1.45）、长链神经酰胺（C16-C18）（HR，1.22；95% CI 1.02,1.45）和 18:1 神经酰胺（HR，1.21；95% CI 1.01,1.46）与传统 CVD 风险因素调整后的更高 CVD 风险相关。